Department of Clinical Pathology/Hematology, Faculty of Medicine, Ain Shams Medical Research Center, Ain Shams University, Cairo, Egypt.
Department of Biochemistry, Faculty of Science, Damietta University, Damietta, Egypt.
J Cell Biochem. 2019 Apr;120(4):6315-6321. doi: 10.1002/jcb.27918. Epub 2018 Oct 25.
Mortality rates of acute lymphoblastic leukemia (ALL) have improved over the past 20 years; however, a significant portion of deaths stems from the lack of prognostic biomarkers, which can direct therapy and overcome drug resistance. microRNA-155a (miRNA-155a) and miRNA-181a are two single-stranded miRNAs involved in the pathogenesis of many types of leukemia and lymphoma and is linked to drug resistance. We investigated their expression levels in 55 patients, 45 diagnosed with ALL and 10 as a control group. We found that miRNA-155a and miRNA-181a were significantly upregulated in the ALL group with both being linked to high levels of minimal residual disease and poor prognosis. miRNA-155a cutoff value was significant in discriminating between high- and low-risk ALL patients as well as between ALL patients and healthy controls, miRNA-181a cutoff value, however, was not significant. Both markers levels were significantly downregulated after therapy. We conclude that miR-155 is correlated with poor prognosis in ALL, whereas we couldn't link miRNA-181a to the prognosis in ALL. Moreover, the marked decrease in their expression after therapy could reflect their impact on disease outcome.
急性淋巴细胞白血病 (ALL) 的死亡率在过去 20 年中有所改善；然而，大量的死亡仍然归因于缺乏预测性生物标志物，这些标志物可以指导治疗并克服耐药性。microRNA-155a (miRNA-155a) 和 miRNA-181a 是两种参与多种类型白血病和淋巴瘤发病机制的单链 miRNA，与耐药性有关。我们调查了 55 名患者的表达水平，其中 45 名被诊断为 ALL，10 名作为对照组。我们发现，miRNA-155a 和 miRNA-181a 在 ALL 组中显著上调，两者均与高微小残留病水平和不良预后相关。miRNA-155a 的截断值在区分高危和低危 ALL 患者以及 ALL 患者和健康对照方面具有显著意义，而 miRNA-181a 的截断值则不显著。治疗后两种标志物的水平均显著下调。我们得出结论，miR-155 与 ALL 预后不良相关，而我们无法将 miRNA-181a 与 ALL 的预后联系起来。此外，治疗后其表达水平的显著下降可能反映了它们对疾病结局的影响。
